Intrinsic value of CryoLife - CRY

Previous Close

$31.03

  Intrinsic Value

$18.37

stock screener

  Rating & Target

sell

-41%

Previous close

$31.03

 
Intrinsic value

$18.37

 
Up/down potential

-41%

 
Rating

sell

We calculate the intrinsic value of CRY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  43.20
  39.38
  35.94
  32.85
  30.06
  27.56
  25.30
  23.27
  21.44
  19.80
  18.32
  16.99
  15.79
  14.71
  13.74
  12.87
  12.08
  11.37
  10.73
  10.16
  9.64
  9.18
  8.76
  8.39
  8.05
  7.74
  7.47
  7.22
  7.00
  6.80
Revenue, $m
  272
  379
  515
  684
  889
  1,134
  1,421
  1,752
  2,128
  2,549
  3,016
  3,529
  4,086
  4,687
  5,331
  6,017
  6,743
  7,510
  8,316
  9,161
  10,045
  10,967
  11,928
  12,928
  13,968
  15,050
  16,174
  17,342
  18,556
  19,817
Variable operating expenses, $m
  234
  312
  411
  534
  683
  862
  1,070
  1,311
  1,584
  1,891
  2,193
  2,566
  2,971
  3,408
  3,876
  4,375
  4,903
  5,461
  6,047
  6,662
  7,304
  7,975
  8,673
  9,401
  10,157
  10,944
  11,761
  12,610
  13,493
  14,410
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  234
  312
  411
  534
  683
  862
  1,070
  1,311
  1,584
  1,891
  2,193
  2,566
  2,971
  3,408
  3,876
  4,375
  4,903
  5,461
  6,047
  6,662
  7,304
  7,975
  8,673
  9,401
  10,157
  10,944
  11,761
  12,610
  13,493
  14,410
Operating income, $m
  37
  67
  104
  150
  206
  273
  351
  441
  544
  659
  823
  963
  1,115
  1,279
  1,455
  1,642
  1,840
  2,049
  2,269
  2,500
  2,741
  2,992
  3,254
  3,527
  3,811
  4,106
  4,413
  4,732
  5,063
  5,407
EBITDA, $m
  82
  114
  155
  206
  268
  341
  428
  527
  640
  767
  907
  1,062
  1,229
  1,410
  1,604
  1,810
  2,029
  2,259
  2,502
  2,756
  3,022
  3,299
  3,588
  3,889
  4,202
  4,528
  4,866
  5,217
  5,582
  5,962
Interest expense (income), $m
  2
  12
  19
  29
  41
  56
  74
  96
  121
  151
  184
  222
  263
  309
  358
  412
  469
  530
  594
  662
  734
  809
  888
  970
  1,055
  1,144
  1,236
  1,333
  1,433
  1,536
  1,644
Earnings before tax, $m
  26
  47
  75
  109
  150
  199
  255
  320
  393
  475
  601
  700
  806
  921
  1,043
  1,173
  1,310
  1,455
  1,607
  1,766
  1,932
  2,105
  2,285
  2,472
  2,667
  2,870
  3,080
  3,299
  3,527
  3,763
Tax expense, $m
  7
  13
  20
  29
  41
  54
  69
  86
  106
  128
  162
  189
  218
  249
  282
  317
  354
  393
  434
  477
  522
  568
  617
  668
  720
  775
  832
  891
  952
  1,016
Net income, $m
  19
  35
  55
  80
  110
  145
  186
  234
  287
  347
  439
  511
  589
  672
  761
  856
  956
  1,062
  1,173
  1,289
  1,410
  1,536
  1,668
  1,805
  1,947
  2,095
  2,249
  2,408
  2,574
  2,747

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  844
  1,176
  1,599
  2,124
  2,762
  3,523
  4,414
  5,442
  6,609
  7,917
  9,368
  10,959
  12,689
  14,556
  16,556
  18,685
  20,942
  23,324
  25,827
  28,451
  31,195
  34,059
  37,043
  40,149
  43,380
  46,739
  50,229
  53,856
  57,626
  61,544
Adjusted assets (=assets-cash), $m
  844
  1,176
  1,599
  2,124
  2,762
  3,523
  4,414
  5,442
  6,609
  7,917
  9,368
  10,959
  12,689
  14,556
  16,556
  18,685
  20,942
  23,324
  25,827
  28,451
  31,195
  34,059
  37,043
  40,149
  43,380
  46,739
  50,229
  53,856
  57,626
  61,544
Revenue / Adjusted assets
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
  0.322
Average production assets, $m
  221
  307
  418
  555
  722
  921
  1,154
  1,423
  1,728
  2,070
  2,449
  2,865
  3,318
  3,806
  4,329
  4,886
  5,476
  6,098
  6,753
  7,439
  8,156
  8,905
  9,685
  10,498
  11,342
  12,220
  13,133
  14,082
  15,067
  16,092
Working capital, $m
  136
  189
  257
  342
  445
  567
  711
  876
  1,064
  1,275
  1,508
  1,764
  2,043
  2,343
  2,665
  3,008
  3,372
  3,755
  4,158
  4,581
  5,022
  5,483
  5,964
  6,464
  6,984
  7,525
  8,087
  8,671
  9,278
  9,909
Total debt, $m
  353
  530
  754
  1,032
  1,370
  1,774
  2,246
  2,790
  3,409
  4,102
  4,871
  5,715
  6,632
  7,621
  8,681
  9,810
  11,006
  12,268
  13,595
  14,985
  16,440
  17,957
  19,539
  21,185
  22,898
  24,678
  26,528
  28,450
  30,448
  32,525
Total liabilities, $m
  447
  623
  847
  1,125
  1,464
  1,867
  2,340
  2,884
  3,503
  4,196
  4,965
  5,808
  6,725
  7,715
  8,774
  9,903
  11,099
  12,362
  13,688
  15,079
  16,533
  18,051
  19,633
  21,279
  22,991
  24,771
  26,621
  28,544
  30,542
  32,618
Total equity, $m
  397
  553
  751
  998
  1,298
  1,656
  2,075
  2,558
  3,106
  3,721
  4,403
  5,151
  5,964
  6,841
  7,781
  8,782
  9,843
  10,962
  12,139
  13,372
  14,662
  16,008
  17,410
  18,870
  20,389
  21,967
  23,608
  25,313
  27,084
  28,926
Total liabilities and equity, $m
  844
  1,176
  1,598
  2,123
  2,762
  3,523
  4,415
  5,442
  6,609
  7,917
  9,368
  10,959
  12,689
  14,556
  16,555
  18,685
  20,942
  23,324
  25,827
  28,451
  31,195
  34,059
  37,043
  40,149
  43,380
  46,738
  50,229
  53,857
  57,626
  61,544
Debt-to-equity ratio
  0.890
  0.960
  1.000
  1.030
  1.060
  1.070
  1.080
  1.090
  1.100
  1.100
  1.110
  1.110
  1.110
  1.110
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
  1.120
Adjusted equity ratio
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  19
  35
  55
  80
  110
  145
  186
  234
  287
  347
  439
  511
  589
  672
  761
  856
  956
  1,062
  1,173
  1,289
  1,410
  1,536
  1,668
  1,805
  1,947
  2,095
  2,249
  2,408
  2,574
  2,747
Depreciation, amort., depletion, $m
  44
  47
  51
  56
  62
  69
  77
  86
  96
  108
  84
  99
  114
  131
  149
  168
  189
  210
  233
  257
  281
  307
  334
  362
  391
  421
  453
  486
  520
  555
Funds from operations, $m
  63
  82
  106
  136
  171
  214
  263
  319
  383
  455
  524
  610
  703
  803
  911
  1,025
  1,145
  1,272
  1,406
  1,545
  1,691
  1,843
  2,002
  2,167
  2,338
  2,516
  2,702
  2,894
  3,094
  3,302
Change in working capital, $m
  41
  53
  68
  85
  103
  123
  144
  165
  188
  211
  234
  256
  279
  301
  322
  343
  363
  383
  403
  422
  442
  461
  480
  500
  520
  541
  562
  584
  607
  631
Cash from operations, $m
  22
  29
  38
  51
  69
  91
  119
  154
  195
  244
  290
  353
  424
  503
  589
  682
  782
  889
  1,003
  1,123
  1,249
  1,382
  1,521
  1,667
  1,818
  1,976
  2,140
  2,310
  2,487
  2,671
Maintenance CAPEX, $m
  -5
  -8
  -11
  -14
  -19
  -25
  -32
  -40
  -49
  -60
  -71
  -84
  -99
  -114
  -131
  -149
  -168
  -189
  -210
  -233
  -257
  -281
  -307
  -334
  -362
  -391
  -421
  -453
  -486
  -520
New CAPEX, $m
  -66
  -87
  -111
  -137
  -167
  -199
  -233
  -269
  -305
  -342
  -379
  -416
  -452
  -488
  -523
  -557
  -590
  -623
  -655
  -686
  -717
  -749
  -780
  -812
  -845
  -878
  -913
  -948
  -986
  -1,024
Cash from investing activities, $m
  -71
  -95
  -122
  -151
  -186
  -224
  -265
  -309
  -354
  -402
  -450
  -500
  -551
  -602
  -654
  -706
  -758
  -812
  -865
  -919
  -974
  -1,030
  -1,087
  -1,146
  -1,207
  -1,269
  -1,334
  -1,401
  -1,472
  -1,544
Free cash flow, $m
  -50
  -66
  -83
  -101
  -118
  -133
  -145
  -154
  -159
  -158
  -161
  -147
  -127
  -100
  -65
  -24
  23
  77
  138
  204
  276
  352
  434
  520
  611
  706
  806
  909
  1,016
  1,127
Issuance/(repayment) of debt, $m
  134
  176
  224
  278
  338
  403
  472
  544
  618
  693
  769
  843
  917
  989
  1,060
  1,129
  1,196
  1,262
  1,327
  1,391
  1,454
  1,518
  1,582
  1,646
  1,712
  1,780
  1,850
  1,922
  1,998
  2,077
Issuance/(repurchase) of shares, $m
  101
  122
  144
  167
  190
  213
  233
  249
  261
  268
  243
  237
  225
  205
  179
  145
  104
  57
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  235
  298
  368
  445
  528
  616
  705
  793
  879
  961
  1,012
  1,080
  1,142
  1,194
  1,239
  1,274
  1,300
  1,319
  1,331
  1,391
  1,454
  1,518
  1,582
  1,646
  1,712
  1,780
  1,850
  1,922
  1,998
  2,077
Total cash flow (excl. dividends), $m
  186
  232
  285
  345
  411
  483
  560
  639
  721
  804
  851
  933
  1,015
  1,095
  1,173
  1,249
  1,324
  1,397
  1,468
  1,595
  1,730
  1,870
  2,016
  2,167
  2,324
  2,486
  2,656
  2,831
  3,014
  3,204
Retained Cash Flow (-), $m
  -119
  -156
  -199
  -247
  -300
  -358
  -419
  -483
  -548
  -615
  -682
  -748
  -813
  -877
  -940
  -1,001
  -1,061
  -1,119
  -1,177
  -1,233
  -1,290
  -1,346
  -1,403
  -1,460
  -1,518
  -1,579
  -1,641
  -1,705
  -1,772
  -1,842
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  66
  75
  86
  98
  111
  125
  141
  157
  173
  189
  169
  185
  202
  218
  233
  248
  263
  278
  292
  361
  440
  524
  613
  707
  805
  908
  1,015
  1,126
  1,242
  1,362
Discount rate, %
  7.70
  8.09
  8.49
  8.91
  9.36
  9.83
  10.32
  10.83
  11.38
  11.95
  12.54
  13.17
  13.83
  14.52
  15.25
  16.01
  16.81
  17.65
  18.53
  19.46
  20.43
  21.45
  22.52
  23.65
  24.83
  26.07
  27.38
  28.75
  30.18
  31.69
PV of cash for distribution, $m
  61
  65
  67
  70
  71
  72
  71
  69
  66
  61
  46
  42
  37
  33
  28
  23
  19
  15
  12
  10
  9
  7
  6
  4
  3
  2
  1
  1
  1
  0
Current shareholders' claim on cash, %
  91.9
  85.5
  80.4
  76.3
  72.9
  70.1
  67.8
  65.9
  64.3
  63.0
  62.0
  61.2
  60.6
  60.1
  59.7
  59.4
  59.3
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2
  59.2

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife's SynerGraft technology.

FINANCIAL RATIOS  of  CryoLife (CRY)

Valuation Ratios
P/E Ratio 92.7
Price to Sales 5.7
Price to Book 4.9
Price to Tangible Book
Price to Cash Flow 51
Price to Free Cash Flow 72.9
Growth Rates
Sales Growth Rate 23.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 8.4%
Financial Strength
Quick Ratio 11
Current Ratio 1
LT Debt to Equity 32.1%
Total Debt to Equity 34.4%
Interest Coverage 10
Management Effectiveness
Return On Assets 4.9%
Ret/ On Assets - 3 Yr. Avg. 3.7%
Return On Total Capital 5%
Ret/ On T. Cap. - 3 Yr. Avg. 4.1%
Return On Equity 6%
Return On Equity - 3 Yr. Avg. 4.5%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 66.1%
Gross Margin - 3 Yr. Avg. 63.7%
EBITDA Margin 15.6%
EBITDA Margin - 3 Yr. Avg. 11.4%
Operating Margin 11.7%
Oper. Margin - 3 Yr. Avg. 7.1%
Pre-Tax Margin 10%
Pre-Tax Margin - 3 Yr. Avg. 6.8%
Net Profit Margin 6.1%
Net Profit Margin - 3 Yr. Avg. 4.6%
Effective Tax Rate 38.9%
Eff/ Tax Rate - 3 Yr. Avg. 31.5%
Payout Ratio 0%

CRY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CRY stock intrinsic value calculation we used $189.702 million for the last fiscal year's total revenue generated by CryoLife. The default revenue input number comes from 0001 income statement of CryoLife. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CRY stock valuation model: a) initial revenue growth rate of 43.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.7%, whose default value for CRY is calculated based on our internal credit rating of CryoLife, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CryoLife.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CRY stock the variable cost ratio is equal to 92.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CRY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for CryoLife.

Corporate tax rate of 27% is the nominal tax rate for CryoLife. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CRY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CRY are equal to 81.2%.

Life of production assets of 29 years is the average useful life of capital assets used in CryoLife operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CRY is equal to 50%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $277.058 million for CryoLife - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 36.775 million for CryoLife is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CryoLife at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
OCUL Ocular Therape 5.56 0.23  str.sell
BAX Baxter Interna 63.48 13.73  str.sell
BSX Boston Scienti 38.60 12.09  str.sell
EW Edwards Lifesc 153.18 121.67  hold
IART Integra LifeSc 55.11 59.90  hold
BVX Bovie Medical 6.65 0.15  str.sell
JNJ Johnson&Johnso 145.34 176.79  buy

COMPANY NEWS

▶ CryoLife: 3Q Earnings Snapshot   [06:09PM  Associated Press]
▶ CryoLife, Inc. to Host Earnings Call   [Aug-07-18 06:30AM  ACCESSWIRE]
▶ CryoLife: 2Q Earnings Snapshot   [05:52PM  Associated Press]
▶ CryoLife adds health system CEO to board of directors   [Jun-21-18 02:45PM  American City Business Journals]
▶ Marna Borgstrom Joins CryoLife Board of Directors   [Jun-19-18 05:00PM  PR Newswire]
▶ CryoLife: 1Q Earnings Snapshot   [May-03-18 05:11AM  Associated Press]
▶ CryoLife Reports First Quarter 2018 Results   [May-02-18 05:24PM  PR Newswire]
▶ CryoLife, Inc. to Host Earnings Call   [06:00AM  ACCESSWIRE]
▶ CryoLife reports 4Q loss   [05:04AM  Associated Press]
▶ ETFs with exposure to CryoLife, Inc. : December 18, 2017   [Dec-18-17 03:16PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : December 7, 2017   [Dec-07-17 01:24PM  Capital Cube]
▶ CryoLife Completes Acquisition of JOTEC   [Dec-01-17 05:04PM  PR Newswire]
▶ ETFs with exposure to CryoLife, Inc. : November 27, 2017   [Nov-27-17 12:54PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : November 13, 2017   [Nov-13-17 12:07PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : November 3, 2017   [Nov-03-17 12:04PM  Capital Cube]
▶ CryoLife, Inc. to Host Earnings Call   [06:05AM  ACCESSWIRE]
▶ CryoLife posts 3Q profit   [Oct-30-17 06:51PM  Associated Press]
▶ Investor Network: CryoLife, Inc. to Host Earnings Call   [Oct-11-17 07:00AM  ACCESSWIRE]
▶ CryoLife Announces Definitive Agreement to Acquire JOTEC   [Oct-10-17 05:00PM  PR Newswire]
▶ Jeffrey H. Burbank Joins CryoLife Board of Directors   [Oct-02-17 08:04AM  PR Newswire]
▶ ETFs with exposure to CryoLife, Inc. : August 14, 2017   [Aug-14-17 04:26PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : August 4, 2017   [Aug-03-17 08:04PM  Capital Cube]
▶ Investor Network: CryoLife, Inc. to Host Earnings Call   [Jul-25-17 06:00AM  Accesswire]
▶ CryoLife posts 2Q profit   [Jul-24-17 10:12PM  Associated Press]
▶ ETFs with exposure to CryoLife, Inc. : June 26, 2017   [Jun-26-17 03:42PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : June 6, 2017   [Jun-06-17 11:39AM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : May 22, 2017   [May-22-17 01:31PM  Capital Cube]
▶ ETFs with exposure to CryoLife, Inc. : May 8, 2017   [May-08-17 04:21PM  Capital Cube]
▶ CryoLife, Inc. Value Analysis (NYSE:CRY) : April 28, 2017   [Apr-28-17 04:44PM  Capital Cube]
▶ Why CryoLife Inc. Jumped Higher   [01:20PM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.